Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report

Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report

Dragana Jovanovic,1,2 Ruza Stevic,1,2 Marta Velinovic,2 Milica Kontic,1,2 Dragana Maric,1,2 Jelena Spasic,3 Davorin Radosavljevic3 1Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 2University Hospital of Pulmonology, Clinical Center of Serbia, Belgrade, Serbia; 3Institute for Oncolog...

Full description

Bibliographic Details
Main Authors:	Jovanovic D, Stevic R, Velinovic M, Kontic M, Maric D, Spasic J, Radosavljevic D
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-09-01
Series:	OncoTargets and Therapy
Subjects:	lung adenocarcinoma erlotinib exon 19 deletion EGFR durable remission
Online Access:	https://www.dovepress.com/durable-complete-remission-of-poor-performance-status-metastatic-lung--peer-reviewed-article-OTT

Similar Items

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
by: He YY, et al.
Published: (2016-04-01)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
by: Jiang-Yong Yu, et al.
Published: (2016-03-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
by: Zsolt Markóczy, et al.
Published: (2018-05-01)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)

Role of Erlotinib 100 mg/d in the Treatment of  Advanced Adenocarcinoma Lung Cancer Failed to Previous Chemotherapy
by: Chunlei SHI, et al.
Published: (2011-06-01)

Effects of Erlotinib on 34 Patients with Advanced Squamous Cell Lung Cancer
by: Fang CHENG, et al.
Published: (2016-10-01)

Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma
by: Michelle Levy, et al.
Published: (2017-12-01)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
by: Cavazzoni Andrea, et al.
Published: (2012-12-01)

Russian multicenter retrospective study: preliminary data concerning clinical and molecular genetic characteristics in long-term responders to erlotinib
by: A V Smolin, et al.
Published: (2014-09-01)

Rapid Response to High-Dose, Pulsatile Erlotinib in Afatinib-Refractory Leptomeningeal Carcinomatosis from Adenocarcinoma of the Lung: A Case Report
by: Frank S. Fan
Published: (2016-09-01)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
by: Huang K, et al.
Published: (2018-09-01)

Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
by: Ye Jiang, et al.
Published: (2018-11-01)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020-03-01)

Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer
by: Shi L, et al.
Published: (2017-03-01)

The exon 19-deleted EGFR undergoes ubiquitylation-mediated endocytic degradation via dynamin activity-dependent and -independent mechanisms
by: Taishu Wang, et al.
Published: (2018-07-01)

Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab
by: Joan Manel Gasent Blesa, et al.
Published: (2012-12-01)

Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
by: Ya Gao, et al.
Published: (2018-12-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients
by: Yuh-Min Chen, et al.
Published: (2015-03-01)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
by: Paola Ulivi, et al.
Published: (2014-12-01)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression
by: Nobutomo Ikarashi, et al.
Published: (2020-04-01)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
by: Reham Abdel-Wahab, et al.
Published: (2018-05-01)

Type I Collagen Aging Increases Expression and Activation of EGFR and Induces Resistance to Erlotinib in Lung Carcinoma in 3D Matrix Model
by: Thomas Sarazin, et al.
Published: (2020-09-01)

Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner
by: Edit Kiss, et al.
Published: (2020-05-01)

Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy
by: Yuling Zhou, MS, et al.
Published: (2020-06-01)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
by: Nahomi Tokudome, et al.
Published: (2020-02-01)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
by: Kazuki Gohara, et al.
Published: (2021-01-01)

Erlotinib Treatment in a Case of Lung Adenocarcinoma Mimicking Interstitial Lung Disease
by: Şenay Yılmaz, et al.
Published: (2017-04-01)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
by: Nobuhiko Seki, et al.
Published: (2019-01-01)

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation
by: Liu J, et al.
Published: (2016-02-01)

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
by: Zwitter Matjaz, et al.
Published: (2014-12-01)

Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I
by: Seigo Minami, et al.
Published: (2019-02-01)

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
by: Alessandro Russo, et al.
Published: (2019-03-01)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
by: Lin L, et al.
Published: (2020-09-01)

The ways of erlotinib resistance overcoming in treatment of patients with eGFr mutated nsClC
by: S V Orlov
Published: (2013-12-01)

Prognostic impact of initial maximum standardized uptake value of 18F-FDG PET/CT on treatment response in patients with metastatic lung adenocarcinoma treated with erlotinib
by: Kus T, et al.
Published: (2015-12-01)

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients
by: Tatsuya Imabayashi, et al.
Published: (2019-02-01)

A case of lung adenocarcinoma harboring <it>EGFR</it> mutation and <it>EML4-ALK</it> fusion gene
by: Tanaka Hisashi, et al.
Published: (2012-11-01)

Cannot write session to /tmp/vufind_sessions/sess_283u7t161magl9fh1estnd65td